Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02308228 · ClinicalTrials.gov registry record · Early Phase 1
Metformin to Augment Strength Training Effective Response in Seniors (MASTERS)
A Early Phase 1 study, sponsored by Philip Kern.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 109
- Enrollment target
NCT02308228 is a Early Phase 1 study that has completed, run by Philip Kern. The registered enrollment target is 109 participants.
The verdict
NCT02308228, a Early Phase 1 study, has completed, sponsored by Philip Kern.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 109 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a commonly prescribed drug, metformin, can enhance the benefits seen during resistance exercise such as increased muscle mass and strength.
Interventions
- DRUG Metformin
- BEHAVIORAL Progressive Resistance Training
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2015-01-14 |
| Est. Completion | 2018-06-28 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02308228
The ClinicalTrials.gov registry entry for NCT02308228 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Philip Kern, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Metformin is the first listed.
NCT02308228 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02308228 about?
NCT02308228 is a clinical study titled "Metformin to Augment Strength Training Effective Response in Seniors (MASTERS)". The purpose of this study is to determine whether a commonly prescribed drug, metformin, can enhance the benefits seen during resistance exercise such as increased muscle mass and strength.
What is the current status of trial NCT02308228?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 109 participants. The study started on 2015-01-14. Estimated completion is 2018-06-28.
What interventions are being tested in trial NCT02308228?
The interventions under investigation include: Metformin (DRUG), Progressive Resistance Training (BEHAVIORAL).
Who is sponsoring clinical trial NCT02308228?
This trial is sponsored by Philip Kern, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.